Cargando…

Understanding and Kinetic Modeling of Complex Degradation Pathways in the Solid Dosage Form: The Case of Saxagliptin

Drug substance degradation kinetics in solid dosage forms is rarely mechanistically modeled due to several potential micro-environmental and manufacturing related effects that need to be integrated into rate laws. The aim of our work was to construct a model capable of predicting individual degradat...

Descripción completa

Detalles Bibliográficos
Autores principales: Robnik, Blaž, Likozar, Blaž, Wang, Baifan, Stanić Ljubin, Tijana, Časar, Zdenko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781548/
https://www.ncbi.nlm.nih.gov/pubmed/31480788
http://dx.doi.org/10.3390/pharmaceutics11090452
_version_ 1783457392229351424
author Robnik, Blaž
Likozar, Blaž
Wang, Baifan
Stanić Ljubin, Tijana
Časar, Zdenko
author_facet Robnik, Blaž
Likozar, Blaž
Wang, Baifan
Stanić Ljubin, Tijana
Časar, Zdenko
author_sort Robnik, Blaž
collection PubMed
description Drug substance degradation kinetics in solid dosage forms is rarely mechanistically modeled due to several potential micro-environmental and manufacturing related effects that need to be integrated into rate laws. The aim of our work was to construct a model capable of predicting individual degradation product concentrations, taking into account also formulation composition parameters. A comprehensive study was done on active film-coated tablets, manufactured by layering of the drug substance, a primary amine compound saxagliptin, onto inert tablet cores. Formulation variables like polyethylene glycol (PEG) 6000 amount and film-coat polymer composition are incorporated into the model, and are connected to saxagliptin degradation, via formation of reactive impurities. Derived reaction equations are based on mechanisms supported by ab initio calculations of individual reaction activation energies. Alongside temperature, relative humidity, and reactant concentration, the drug substance impurity profile is dependent on micro-environmental pH, altered by formation of acidic PEG degradation products. A consequence of pH lowering, due to formation of formic acid, is lower formation of main saxagliptin degradation product epi-cyclic amidine, a better resistance of formulation to high relative humidity conditions, and satisfactory tablet appearance. Discovered insights enhance the understanding of degradational behavior of similarly composed solid dosage forms on overall drug product quality and may be adopted by pharmaceutical scientists for the design of a stable formulation.
format Online
Article
Text
id pubmed-6781548
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67815482019-10-30 Understanding and Kinetic Modeling of Complex Degradation Pathways in the Solid Dosage Form: The Case of Saxagliptin Robnik, Blaž Likozar, Blaž Wang, Baifan Stanić Ljubin, Tijana Časar, Zdenko Pharmaceutics Article Drug substance degradation kinetics in solid dosage forms is rarely mechanistically modeled due to several potential micro-environmental and manufacturing related effects that need to be integrated into rate laws. The aim of our work was to construct a model capable of predicting individual degradation product concentrations, taking into account also formulation composition parameters. A comprehensive study was done on active film-coated tablets, manufactured by layering of the drug substance, a primary amine compound saxagliptin, onto inert tablet cores. Formulation variables like polyethylene glycol (PEG) 6000 amount and film-coat polymer composition are incorporated into the model, and are connected to saxagliptin degradation, via formation of reactive impurities. Derived reaction equations are based on mechanisms supported by ab initio calculations of individual reaction activation energies. Alongside temperature, relative humidity, and reactant concentration, the drug substance impurity profile is dependent on micro-environmental pH, altered by formation of acidic PEG degradation products. A consequence of pH lowering, due to formation of formic acid, is lower formation of main saxagliptin degradation product epi-cyclic amidine, a better resistance of formulation to high relative humidity conditions, and satisfactory tablet appearance. Discovered insights enhance the understanding of degradational behavior of similarly composed solid dosage forms on overall drug product quality and may be adopted by pharmaceutical scientists for the design of a stable formulation. MDPI 2019-09-02 /pmc/articles/PMC6781548/ /pubmed/31480788 http://dx.doi.org/10.3390/pharmaceutics11090452 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Robnik, Blaž
Likozar, Blaž
Wang, Baifan
Stanić Ljubin, Tijana
Časar, Zdenko
Understanding and Kinetic Modeling of Complex Degradation Pathways in the Solid Dosage Form: The Case of Saxagliptin
title Understanding and Kinetic Modeling of Complex Degradation Pathways in the Solid Dosage Form: The Case of Saxagliptin
title_full Understanding and Kinetic Modeling of Complex Degradation Pathways in the Solid Dosage Form: The Case of Saxagliptin
title_fullStr Understanding and Kinetic Modeling of Complex Degradation Pathways in the Solid Dosage Form: The Case of Saxagliptin
title_full_unstemmed Understanding and Kinetic Modeling of Complex Degradation Pathways in the Solid Dosage Form: The Case of Saxagliptin
title_short Understanding and Kinetic Modeling of Complex Degradation Pathways in the Solid Dosage Form: The Case of Saxagliptin
title_sort understanding and kinetic modeling of complex degradation pathways in the solid dosage form: the case of saxagliptin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781548/
https://www.ncbi.nlm.nih.gov/pubmed/31480788
http://dx.doi.org/10.3390/pharmaceutics11090452
work_keys_str_mv AT robnikblaz understandingandkineticmodelingofcomplexdegradationpathwaysinthesoliddosageformthecaseofsaxagliptin
AT likozarblaz understandingandkineticmodelingofcomplexdegradationpathwaysinthesoliddosageformthecaseofsaxagliptin
AT wangbaifan understandingandkineticmodelingofcomplexdegradationpathwaysinthesoliddosageformthecaseofsaxagliptin
AT stanicljubintijana understandingandkineticmodelingofcomplexdegradationpathwaysinthesoliddosageformthecaseofsaxagliptin
AT casarzdenko understandingandkineticmodelingofcomplexdegradationpathwaysinthesoliddosageformthecaseofsaxagliptin